Phenylephrine hydrochloride - Generic Drug Details

What are the generic drug sources for phenylephrine hydrochloride and what is the scope of patent protection?

Phenylephrine hydrochloride is the generic ingredient in thirteen branded drugs marketed by Alcon, Caplin, Gland, Mankind Pharma, Paragon Bioteck, Dr Reddys Labs Sa, Hikma, Accord Hlthcare, Amneal, Aspiro, Avet Lifesciences, Be Pharms, Eugia Pharma, Fresenius Kabi Usa, Hainan Poly, Meitheal, Milla Pharms, Ph Health, Sagent Pharms Inc, Sandoz, Somerset Theraps Llc, Exela Pharma, Ani Pharms, Genus, Halsey, G And W Labs Inc, Amneal Pharms, Cenci, Xttrium Labs Inc, Allergan, and Eyenovia, and is included in forty-one NDAs. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Phenylephrine hydrochloride has one patent family member in one country.

There are twelve drug master file entries for phenylephrine hydrochloride. Thirty-seven suppliers are listed for this compound.

Summary for phenylephrine hydrochloride

International Patents:	1
US Patents:	7
Tradenames:	13
Applicants:	31
NDAs:	41
Drug Master File Entries:	12
Finished Product Suppliers / Packagers:	37
Raw Ingredient (Bulk) Api Vendors:	71
Clinical Trials:	378
Patent Applications:	3,339
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for phenylephrine hydrochloride
What excipients (inactive ingredients) are in phenylephrine hydrochloride?	phenylephrine hydrochloride excipients list
DailyMed Link:	phenylephrine hydrochloride at DailyMed

Recent Clinical Trials for phenylephrine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Follea International Limited	PHASE3
Daniel Alain, Inc.	PHASE3
Applied Biology, Inc.	PHASE3

See all phenylephrine hydrochloride clinical trials

Pharmacology for phenylephrine hydrochloride

Drug Class	alpha-1 Adrenergic Agonist
Mechanism of Action	Adrenergic alpha1-Agonists

Medical Subject Heading (MeSH) Categories for phenylephrine hydrochloride

Adrenergic alpha-1 Receptor Agonists

Cardiotonic Agents

Mydriatics

Nasal Decongestants

Sympathomimetics

Vasoconstrictor Agents

Anatomical Therapeutic Chemical (ATC) Classes for phenylephrine hydrochloride

C01CA	Adrenergic and dopaminergic agents
C01C	CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01	CARDIAC THERAPY
C	Cardiovascular system

C05AX	Other agents for treatment of hemorrhoids and anal fissures for topical use
C05A	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05	VASOPROTECTIVES
C	Cardiovascular system

R01AA	Sympathomimetics, plain
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R01AB	Sympathomimetics, combinations excl. corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R01BA	Sympathomimetics
R01B	NASAL DECONGESTANTS FOR SYSTEMIC USE
R01	NASAL PREPARATIONS
R	Respiratory system

S01FB	Sympathomimetics excl. antiglaucoma preparations
S01F	MYDRIATICS AND CYCLOPLEGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01GA	Sympathomimetics used as decongestants
S01G	DECONGESTANTS AND ANTIALLERGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for phenylephrine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hainan Poly	PHENYLEPHRINE HYDROCHLORIDE	phenylephrine hydrochloride	SOLUTION;INTRAVENOUS	218412-002	Mar 14, 2024	AP1	RX	No	No
Accord Hlthcare	PHENYLEPHRINE HYDROCHLORIDE	phenylephrine hydrochloride	SOLUTION;INTRAVENOUS	213237-003	Jul 1, 2020		DISCN	No	No
Milla Pharms	PHENYLEPHRINE HYDROCHLORIDE	phenylephrine hydrochloride	SOLUTION;INTRAVENOUS	211081-003	Jul 17, 2020	AP1	RX	No	No
Hikma	PHENYLEPHRINE HYDROCHLORIDE	phenylephrine hydrochloride	SOLUTION;INTRAVENOUS	203826-002	Jun 19, 2019	AP2	RX	Yes	Yes
Hikma	IMMPHENTIV	phenylephrine hydrochloride	SOLUTION;INTRAVENOUS	203826-005	Mar 9, 2023		RX	Yes	Yes	11,471,400		Y

International Patents for phenylephrine hydrochloride

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2015073696

Supplementary Protection Certificates for phenylephrine hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1534313	92923	Luxembourg		PRODUCT NAME: UNE SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION: 20150730
1534313	15C0090	France		PRODUCT NAME: SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/15/1018 20150728
1534313	2015/071	Ireland		PRODUCT NAME: AN OCULAR IRRIGATION SOLUTION COMPRISING PHENYLEPHRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND KETOROLAC OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/1018 20150728

Phenylephrine Hydrochloride: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Market Landscape Analysis for Phenylephrine Hydrochloride

Phenylephrine hydrochloride (PE) is an alpha-1 adrenergic receptor agonist primarily used as a nasal decongestant. Its market presence is characterized by consistent demand, driven by the prevalence of upper respiratory infections and allergies. The global market for PE is segmented by application (oral, nasal spray, injectable), by distribution channel (hospital pharmacies, retail pharmacies, online pharmacies), and by region.

Key market drivers include an aging population, increasing prevalence of allergic rhinitis, and the over-the-counter (OTC) availability of many PE-containing products. However, the market faces challenges related to regulatory scrutiny, particularly concerning its efficacy as an oral decongestant, and the availability of alternative treatments.

The efficacy debate surrounding oral PE, notably highlighted by the U.S. Food and Drug Administration's (FDA) Non-Prescription Drug Advisory Committee in October 2023, has introduced a significant variable. This committee recommended the removal of oral PE from the market, citing insufficient evidence of effectiveness at labeled doses. This recommendation, if adopted by the FDA, could substantially reshape the market. The immediate impact would likely be a shift towards alternative oral decongestants or increased reliance on nasal spray formulations.

Market Size and Growth Projections:

The global phenylephrine hydrochloride market was valued at approximately USD 1.5 billion in 2022 [1]. Projections prior to the FDA committee's recommendation indicated a Compound Annual Growth Rate (CAGR) of 4.5% to 5.5% from 2023 to 2028, driven by sustained demand for OTC cold and allergy medications [2]. However, these projections are subject to revision based on regulatory outcomes.

Regional Breakdown:

• North America: Represents the largest market share due to high per capita consumption of OTC medications and a well-established pharmaceutical distribution network. The U.S. market is particularly significant.
• Europe: Holds a substantial market share, with strong demand in countries like Germany, the UK, and France. Regulatory frameworks and consumer preferences influence regional growth.
• Asia Pacific: Exhibits the fastest growth potential, fueled by increasing healthcare expenditure, a growing population, and a rising awareness of health and wellness.
• Rest of the World: Includes Latin America, the Middle East, and Africa, contributing a smaller but growing share to the global market.

Competitive Landscape:

The PE market is fragmented, with numerous manufacturers and formulators. Key players include global pharmaceutical companies and generic drug manufacturers. Competition is primarily based on product pricing, distribution network, and product portfolio diversification. Companies that can adapt to evolving regulatory landscapes and demonstrate product efficacy will likely maintain or gain market share.

Table 1: Global Phenylephrine Hydrochloride Market Value (USD Billion)

Year	Market Value
2022	1.50
2023 (est.)	1.58
2024 (proj.)	1.66
2025 (proj.)	1.74

Source: Industry analysis and market research reports.

Regulatory Scrutiny and Efficacy Concerns

The efficacy of oral phenylephrine hydrochloride has been a subject of scientific and regulatory review for several years. In October 2023, the FDA's Non-Prescription Drug Advisory Committee unanimously voted that oral phenylephrine is not effective for treating nasal congestion when used at recommended doses [3]. This decision was based on a review of scientific literature and an FDA-commissioned study, which concluded that oral PE likely does not provide a significant benefit over a placebo.

Key Points of Regulatory Review:

• FDA Advisory Committee Recommendation: The committee's vote advises the FDA to consider removing oral PE from the market. This process typically involves a public comment period and a formal FDA decision.
• Mechanism of Action: PE is a vasoconstrictor that reduces swelling in nasal passages. However, when taken orally, it undergoes significant first-pass metabolism in the liver, converting it into a less potent metabolite (meta-sympathol). This metabolic pathway is believed to significantly reduce its effectiveness when administered orally at doses that are safe and well-tolerated.
• Comparison with Pseudoephedrine: Pseudoephedrine, another oral decongestant, was previously restricted due to its diversion for illicit methamphetamine production. This led to the widespread substitution of pseudoephedrine with phenylephrine in many OTC products. The current review suggests that this substitution may have compromised product efficacy.
• Potential Impact on Market: If the FDA adopts the committee's recommendation, it could lead to the recall of all oral PE-containing products. This would necessitate a rapid market shift towards alternative oral decongestants, such as second-generation antihistamines with decongestant properties or other nasal formulations.
• Nasal Sprays and Injectables: The efficacy concerns primarily target oral formulations. Phenylephrine hydrochloride in nasal spray and injectable forms is generally considered effective and is not under the same level of scrutiny for efficacy.

Timeline of Regulatory Developments:

• Pre-2023: Ongoing scientific discussions and limited studies on oral PE efficacy.
• October 2023: FDA Non-Prescription Drug Advisory Committee meeting and unanimous vote against oral PE efficacy.
• Post-October 2023: Public comment period on the committee's recommendation.
• Future (Est. 6-12 months post-comment period): Potential FDA ruling on the market status of oral PE.

The financial trajectory of PE manufacturers and marketers will be directly influenced by the FDA's final decision. Companies heavily invested in oral PE formulations may face significant inventory write-offs and a need for rapid product line adjustments.

Financial Trajectory and Investment Outlook

The financial trajectory of phenylephrine hydrochloride is at a critical juncture due to the aforementioned regulatory challenges. Prior to the FDA advisory committee's recommendation, the market was characterized by stable demand and predictable revenue streams, particularly for companies with established OTC brands.

Investment Considerations:

• Risk Associated with Oral Formulations: Companies with significant revenue derived from oral PE products face substantial downside risk. An FDA ban would necessitate significant product reformulation or withdrawal, impacting sales and potentially requiring write-downs of existing inventory.
• Opportunities in Alternative Formulations: The potential removal of oral PE could create opportunities for manufacturers of alternative oral decongestants (e.g., those containing nasalopharyngeal decongestant ingredients with proven efficacy) or those with well-established nasal spray formulations of phenylephrine or other effective ingredients.
• Generic vs. Branded Products: The PE market includes both branded and generic products. Generic manufacturers may be more vulnerable to shifts in demand due to price sensitivity. Branded manufacturers may have more resources to pivot to alternative product lines or invest in R&D for new formulations.
• Supply Chain Impact: Disruptions in the supply chain are possible if a widespread recall of oral PE products is mandated. This could affect raw material suppliers and contract manufacturers specializing in these formulations.
• Investor Sentiment: Investor sentiment towards companies heavily reliant on oral PE is likely to become increasingly cautious. Companies that demonstrate a diversified product portfolio or a clear strategy for adapting to regulatory changes will be viewed more favorably.

Financial Metrics to Monitor:

• Revenue from PE-containing products: Track segment-specific revenue reporting by companies.
• Inventory levels: Monitor changes in inventory as regulatory decisions loom.
• R&D expenditure: Observe investments in alternative decongestant technologies or formulations.
• Market share shifts: Analyze changes in market share for competing decongestant categories.

Scenario Analysis:

• Scenario 1: FDA Bans Oral PE: Significant revenue loss for companies with oral PE products, forcing a rapid shift to alternatives. Potential for market consolidation as smaller players exit.
• Scenario 2: FDA Requires Labeling Changes or Additional Studies: Less severe immediate impact, but prolonged uncertainty. Companies might invest in new efficacy studies to support oral PE.
• Scenario 3: Status Quo Maintained: Continued market stability for oral PE, but ongoing scientific debate could resurface.

The investment outlook for companies involved in phenylephrine hydrochloride is therefore highly dependent on the specific formulation and the company's strategic response to regulatory developments. Companies with strong balance sheets and diversified product pipelines are better positioned to navigate this evolving landscape.

Key Takeaways

• The market for phenylephrine hydrochloride (PE) is facing significant uncertainty due to the FDA advisory committee's recommendation to remove oral PE from the market, citing a lack of efficacy.
• Prior to this development, the PE market was valued at approximately USD 1.5 billion and projected to grow steadily, driven by demand for cold and allergy medications.
• North America is the largest market, with Asia Pacific showing the fastest growth potential.
• The competitive landscape is fragmented, with numerous manufacturers vying for market share based on price and distribution.
• If the FDA ban on oral PE is implemented, it will necessitate a rapid shift to alternative oral decongestants or nasal spray formulations.
• Companies heavily reliant on oral PE face substantial financial risks, including potential inventory write-offs and revenue loss, while those with diversified portfolios or strong alternative offerings may find new opportunities.
• The financial trajectory and investment outlook are directly tied to the regulatory outcome, with cautious investor sentiment expected for companies with significant exposure to oral PE products.

Frequently Asked Questions

1. What is the primary reason for the current scrutiny of phenylephrine hydrochloride? The primary reason is the FDA advisory committee's recommendation that oral phenylephrine hydrochloride is not effective for treating nasal congestion at recommended doses due to significant first-pass liver metabolism, which reduces its potency.

2. Will all forms of phenylephrine hydrochloride be removed from the market? The current regulatory focus and committee recommendation specifically target oral formulations of phenylephrine hydrochloride. Nasal spray and injectable forms are generally considered effective and are not under the same scrutiny.

3. What are the potential alternative oral decongestants if oral phenylephrine is banned? Potential alternatives include other oral decongestant ingredients with proven efficacy, such as certain combinations of antihistamines and decongestants, or reintroduction of previously restricted medications where appropriate and safe.

4. How will this regulatory change impact pharmaceutical companies? Companies with significant revenue from oral PE products may experience substantial financial impacts, including product recalls and the need for rapid reformulation or market withdrawal. Companies with diversified portfolios or strong alternative offerings may see increased demand for their products.

5. What is the estimated timeline for a final FDA decision on oral phenylephrine? Following the public comment period on the advisory committee's recommendation, a formal FDA ruling is typically expected within 6 to 12 months, although this timeline can vary.

Citations

[1] Grand View Research. (2023). Phenylephrine Market Size, Share & Trends Analysis Report By Type (Oral, Nasal Spray, Injectable), By Application (Cold & Flu, Allergy, Others), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030.

[2] MarketsandMarkets. (2023). Phenylephrine Market - Global Forecast to 2028.

[3] U.S. Food and Drug Administration. (2023, October 13). FDA Advisory Committee Votes Unanimously That Oral Phenylephrine Is Not Effective. [Press release].